Market Overview

UPDATE: Goldman Sachs Lowers PT on Edwards Lifesciences Following Detailed Model Review

Share:
Related EW
Lawsuit Against Neovasc Comes Back In Favor Of CardiAQ; Ladenburg Thalmann Downgrades, Removes PT
BTIG Downgrades Johnson & Johnson, Admits Buy Thesis 'Had Some Hits & Misses'
No New Record High For S&P 500, But ETFs Based On It Are Soaring (Investor's Business Daily)

In a report published Thursday, Goldman Sachs analyst David H. Roman reiterated a Buy rating on Edwards Lifesciences Corp. (NYSE: EW), but lowered the price target from $112.00 to $106.00.

In the report, Roman noted, “Following a detailed review of our model and management's US transcatheter aortic valve repair (TAVR) guidance, we remain confident in the longer term US ramp of the SAPIEN product suite. In the near term, we are at the low end of the company's 2013 US TAVR guidance of $390-$440 million (GSe at $400 million), but recognize that a stronger uptick from the transapical population (FDA approved in 4Q2012) and new capacity could drive upside. On a longer term basis, we continue to think the company's suite of TAVR products will prove successful at driving adoption in less sick patient categories (and other non-diagnosed/non-treated populations), and view the total US TAVR addressable market as robust.”

Edwards Lifesciences Corp. closed on Wednesday at $81.69.

Latest Ratings for EW

DateFirmActionFromTo
Apr 2016CitigroupMaintainsSell
Apr 2016Cowen & CompanyMaintainsOutperform
Apr 2016JP MorganMaintainsOverweight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!